HOME >> BIOLOGY >> NEWS
Handicapping tuberculosis may be the way to a better vaccine

ll piece of protein, known as a peptide. Upon encountering their specific peptide, T lymphocytes multiply and mount an attack against the pathogen.

After the pathogen has been eliminated, most of the T lymphocytes die, but a small population continues to circulate throughout the body. These cells are known as memory T lymphocytes, and will be poised and ready should the pathogen appear again. The most effective vaccines induce the immune system to produce memory T lymphocytes, which are crucial to establishing life-long immunity.

Of course, pathogens have tricks to evade the immune system. M. tuberculosis lives in the lungs, in immune cells called macrophages. A weapon in TBs arsenal is an enzyme called superoxide dismutase A, or sodA. This enzyme helps TB cover its tracks, so the macrophage doesnt know its infected. Jacobs and his team hypothesized that eliminating this enzymes activity would give macrophages the opportunity to trigger apoptosis, thus prompting a more effective immune response.

So the researchers deleted the gene responsible for shuttling sodA out of the bacterium, effectively disabling sodA activity. When they compared this mutant strain to normal TB, they saw that it did in fact cause increased apoptosis in macrophages grown in culture.

To get a better picture of what was going on, Jacobs and his team used a mouse that had been genetically altered to have all of its T lymphocytes recognize the same peptide. They altered the normal and the apoptosis-inducing strains of TB to produce this peptide.

The researchers transferred thousands of immune cells from the genetically-altered mice into normal mice, which they then infected with the two strains of TB. This procedure gives scientists a magnified view of the immune systems response. Although both strains of TB produce the same amount of peptide, Jacobs expected infection with the apoptosis-inducing strain to elicit a more dramatic immune response.

The rese
'"/>

Contact: Jennifer Michalowski
michalow@hhmi.org
301-215-8576
Howard Hughes Medical Institute
1-Aug-2007


Page: 1 2 3

Related biology news :

1. Einstein researchers prototype vaccine could provide improved protection against tuberculosis
2. Developing a more effective vaccine for tuberculosis
3. Why is long-term therapy required to cure tuberculosis?
4. UA researchers identify new adherence factor, Pili, produced by tuberculosis
5. Shorter tuberculosis therapies could lead to substantial reductions in cases and deaths
6. Pitt phage hunter takes on tuberculosis
7. Cost-effectiveness of treating multidrug-resistant tuberculosis
8. New potential drug target in tuberculosis
9. National Institutes of Health funds $13.7 million for Texas tuberculosis study
10. Einstein researchers find potential new drugs for tuberculosis
11. Studies suggest new targets for tuberculosis treatments

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Handicapping tuberculosis may the way better vaccine

(Date:5/24/2013)... noise in one French Quarter neighborhood of New Orleans ... ordinances, Annette Hurley, PhD, Assistant Professor of Audiology at ... a third-year LSUHSC doctor of audiology student, recommend that ... health. Their case study is published online in the ... ., "An important part of an audiologist,s practice is ...
(Date:5/23/2013)... world,s most popular fruit, can be made both better-tasting ... varieties. , "Working with GM tomatoes that are ... a specific compound, allows us to pinpoint exactly how ... from the John Innes Centre. , The research could ... and shelf life characteristics because even higher levels of ...
(Date:5/23/2013)... suppresses lipid synthesis in the liver, UC Irvine endocrinologists ... liver diseases. , With this finding, Dr. Ellis ... in the field. Study results appear in the May ... , "The dogma in the steroid receptor field for ... the nucleus respond to steroid hormones by regulating genes ...
Breaking Biology News(10 mins):Please do try this at home 2The world's favorite fruit only better-tasting and longer-lasting 2UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2
(Date:5/24/2013)... (PRWEB) May 24, 2013 Vestiage, ... lifestyle company focused on science-based research and development, ... anti-aging cosmeceuticals and nutraceuticals, announced today that it ... States for the sale of Reluma Skin Illuminating ... packet and application by sending an email to ...
(Date:5/23/2013)...  BioScrip, Inc. (NASDAQ: BIOS ) today ... 2013 Global Healthcare Conference to be held June 3-6, ... Richard Smith , President and Chief ... Chief Financial Officer, will present on Monday, June 3, ... About BioScrip BioScrip, Inc. provides comprehensive infusion ...
(Date:5/23/2013)... Ind. , May 23, 2013  Rahal Letterman ... in human cord blood stem cell banking and therapeutics, ... of the No. 16 Acorn Stairlifts Indy car driven ... for the remainder of the IZOD IndyCar 2013 season. ... (RLL) will work to support awareness of umbilical cord ...
(Date:5/23/2013)... PARK, Calif. , May 23, 2013 ... oral treatment for pain has reached an important milestone, ... trial of VBY-036 - a selective cathepsin S inhibitor. ... VBY-036 is a double-blind, randomized, placebo-controlled study designed to ... doses of VBY-036 in healthy adults. "The ...
Breaking Biology Technology:Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3
Cached News: